Washington University School of Medicine in St. LouisNew gene-altering treatment offered for certain blood cancersWashington University School of Medicine in St. LouisAmanda Cashen, MD, examines patient Marie Miceli at Siteman Cancer Center at Barnes-… Continue reading
ForbesFDA Approves Another Amazing And Costly Cancer-Killing Gene TherapyForbesIn 2010, Josh Feldman was on his honeymoon — a globe-spanning trip that at one point involved swimming with humpback whales — when he noticed a "Garbanzo-sized" … Continue reading
|
FDA Approves Yescarta™, Revolutionary CAR–T Immunotherapy for Non-Hodgkin’s Lymphoma Patients
PR Newswire (press release) Yescarta is a Chimeric Antigen Receptor (CAR) T cell therapy, also known as CAR-T. Moffitt Cancer Center’s Frederick Locke, M.D., is the co-lead investigator of the pivotal ZUMA-1 clinical trial that tested the new therapy, which is manufactured by … FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin LymphomaOncLive |
Washington Post |
Cutting-edge immunotherapy treatment approved for another deadly cancer
Washington Post The FDA approval is the latest step forward for the fast-moving field of immunotherapy, which aims to bolster the immune system to attack malignancies. CAR T-cell therapies are among several approaches, along with treatments called checkpoint … Gilead cancer immunotherapy wins US approval with $373000 priceNasdaq Gilead Sciences (GILD) Announces Kite’s Yescarta Becomes First CAR T Therapy Approved by FDA for Treatment of …StreetInsider.com |